Draft:Jacob Lalezari
 | Review waiting, please be patient.
This may take 8 weeks or more, since drafts are reviewed in no specific order. There are 2,299 pending submissions waiting for review.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
Reviewer tools
|
Jacob P. Lalezari | |
|---|---|
| Nationality | American |
| Education | B.A., University of Rochester M.A., University of Virginia M.D., University of Pennsylvania |
| Occupation(s) | Physician, clinical researcher |
| Employer(s) | Quest Clinical Research, CytoDyn Inc. |
| Known for | Antiviral drug development, clinical trials, HIV and COVID-19 research |
| Website | Quest Clinical Research |
 |
Jacob P. Lalezari is an American physician and clinical researcher primarily known for his work in antiviral drug development. He is the Chief Executive Officer and Medical Director of Quest Clinical Research, a San Francisco–based clinical trials center specializing in HIV/AIDS and other viral diseases.[1]
Early life and education
[edit]Lalezari received his medical degree from the University of Pennsylvania School of Medicine and completed his residency in internal medicine at the University of California, San Francisco (UCSF). He went on to complete a fellowship in infectious diseases at UCSF.[2]
Career
[edit]Mount Zion HIV Clinical Research Center (1989–1996)
[edit]From 1989 to 1996, Lalezari served as Director of Clinical Research at the UCSF–affiliated Mount Zion Hospital, where he oversaw early clinical trials of antiviral therapies for HIV/AIDS.[2] That year, he also spoke about the challenges of pursuing an HIV cure in an interview with TheBodyPro.[3]
Quest Clinical Research (1996–present)
[edit]In 1996, Lalezari founded Quest Clinical Research, where he has led hundreds of clinical trials involving investigational agents for HIV, CMV, hepatitis B and C, HPV, herpes simplex virus, influenza, and other infectious diseases.[1] He later provided commentary on gene-editing approaches to HIV therapy in a 2019 interview with Contagion Live.[4] He also served as principal investigator in a Phase 2b trial of PRO 140 monotherapy for HIV, which was covered by Drug Discovery News.[5] He has been recognized in the biotech press for his long-term leadership of Quest Clinical Research, including noting his appointment as CEO and Medical Director since 1997.[6]
CytoDyn Inc.
[edit]In July 2020, Lalezari was appointed Interim Chief Executive Officer of CytoDyn Inc., a biotechnology company developing the monoclonal antibody leronlimab for HIV and COVID-19.[7] He later served as permanent CEO beginning in January 2021.[8] He resigned from the company in 2022.[9] During his tenure at CytoDyn, he publicly commented on the FDA clearance for a Phase II leronlimab trial in microsatellite-stable metastatic colorectal cancer.[10] He was also quoted regarding FDA discussions around leronlimab dosing and development strategy in oncology coverage on CancerNetwork.[11]
Other affiliations
[edit]Lalezari has served as principal investigator in clinical trials sponsored by the National Institutes of Health and numerous pharmaceutical companies. He has published extensively in peer-reviewed journals and lectured internationally on antiviral therapy.[2] He was also quoted on late-stage clinical trial results in a 2025 article syndicated through Gale.[12]
Selected publications
[edit]- Lalezari, Jacob P. (1995). "Safety and efficacy of cidofovir in the treatment of cytomegalovirus retinitis in patients with AIDS". New England Journal of Medicine. 333 (1): 10–16. doi:10.1056/NEJM199507063330103. PMID 7791814.
- Lalezari, Jacob P. (2009). "A phase II clinical trial of the CCR5 antagonist PRO 140 in HIV-infected adults". Journal of Infectious Diseases. 200 (1): 163–168. doi:10.1086/599364. PMID 19432545.
References
[edit]- ^ a b "About Quest Clinical Research". Retrieved August 26, 2025.
- ^ a b c "Henry Stewart Talks: Antiviral Drug Development". Retrieved August 26, 2025.
- ^ "Jacob Lalezari on "Cure" as a Four-Letter Word". TheBodyPro. January 25, 2012. Retrieved August 26, 2025.
- ^ "In Race to Cure HIV, Gene Editing Has Potential and Pitfalls". Contagion Live. March 5, 2019. Retrieved August 26, 2025.
- ^ "PRO 140 quashes HIV". Drug Discovery News. April 2016. Retrieved August 26, 2025.
- ^ "CytoDyn Announces the Addition of Leading Experts in Oncology, Infectious Diseases, and Neuroinflammation to Its Scientific Board of Advisors; Dr. Jay Lalezari to Serve as Outside Scientific Advisor". BioSpace. May 13, 2022. Retrieved August 26, 2025.
- ^ "CytoDyn Appoints Dr. Jacob Lalezari as Interim CEO". July 1, 2020. Retrieved August 26, 2025.
- ^ "CytoDyn Names Dr. Jacob Lalezari as Chief Executive Officer" (Press release). January 1, 2021. Retrieved August 26, 2025.
- ^ "CytoDyn CEO Jacob Lalezari Steps Down". June 15, 2022. Retrieved August 26, 2025.
- ^ "FDA Clears Phase 2 Trial of Leronlimab for Microsatellite-Stable CRC". Targeted Oncology. November 6, 2024. Retrieved August 26, 2025.
- ^ "FDA Holds Meeting for Leronlimab Rationale, Dosing in CCR5+ MSS mCRC". CancerNetwork. August 14, 2024. Retrieved August 26, 2025.
- ^ "Clinical Studies Report". Gale Health Reference Center Academic. 2025. Retrieved August 26, 2025.